

**TRANSFUSION ASSOCIATED DISEASE INVESTIGATION**

HEPATITIS: \_\_\_\_\_ HIV: \_\_\_\_\_ HTLV-I/II: \_\_\_\_\_ OTHER: \_\_\_\_\_

Patient Case # \_\_\_\_\_ MEDIC TADI # \_\_\_\_\_

Reporting Hospital/Address \_\_\_\_\_

Transfusing Hospital/Address \_\_\_\_\_

Diagnosis at time of transfusion \_\_\_\_\_

Date symptoms appeared \_\_\_\_\_ Date reported \_\_\_\_\_

Does patient have history of exposure to hepatitis or any other risk factors? \_\_\_\_\_

Were other products such as PPF, Serum Albumin or Factor VIII administered? YES \_\_\_\_\_ NO \_\_\_\_\_

If yes, list: \_\_\_\_\_

TEST	HBsAg:		Anti-HCV:		Anti-HIV:	
RESULTS:	Anti-HBc:		Anti-HTLV I/II		Western Blot:	

**BLOOD AND BLOOD PRODUCTS TRANSFUSED  
(FOR HEPATITIS - 15 TO 182 DAYS BEFORE ONSET OF VIRAL HEPATITIS)**

UNIT NUMBER	PRODUCT TRANSFUSED	DATE TRANSFUSED	DATE COLLECTED	PREVIOUS DONATIONS	SUBSEQUENT DONATIONS	DATE OF LAST DONATION

MEDIC Notified By: \_\_\_\_\_ Date: \_\_\_\_\_

Donor Investigation Completed By: \_\_\_\_\_ Date: \_\_\_\_\_

Laboratory Review By: \_\_\_\_\_ Date: \_\_\_\_\_

VP & Chief Medical Officer Review By: \_\_\_\_\_ Date: \_\_\_\_\_

FDA Report #: \_\_\_\_\_ By: \_\_\_\_\_ Date: \_\_\_\_\_

MEDIC REGIONAL BLOOD CENTER  
1601 AILOR AVENUE  
KNOXVILLE, TN 37921

MEDIC 4.237 V2  
10/09/2023